XML 55 R44.htm IDEA: XBRL DOCUMENT v3.20.2
SHAREHOLDERS' EQUITY (Tables)
 6 Months Ended
Jun. 30, 2020
Equity [Abstract]  
Schedule of Shareowners' Equity
ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)
Three months ended June 30
 
Six months ended June 30
(In millions)
2020

2019

 
2020

2019

Beginning balance
$
20

$
(16
)
 
$
61

$
(39
)
AOCI before reclasses – net of taxes of $8, $(23), $7 and $15(a)
34

94

 
41

121

Reclasses from AOCI – net of taxes of $(2), $(5), $(14) and $(6)
(7
)
(18
)
 
(55
)
(22
)
AOCI
27

76

 
(14
)
99

Less AOCI attributable to noncontrolling interests
—

—

 
—

1

Investment securities AOCI ending balance
$
47

$
60

 
$
47

$
60

 
 
 
 
 
 
Beginning balance
$
(4,685
)
$
(5,810
)
 
$
(4,818
)
$
(6,134
)
AOCI before reclasses – net of taxes of $25, $13, $20 and $39
(58
)
(308
)
 
(613
)
(1
)
Reclasses from AOCI – net of taxes of $0, $0, $0 and $(4)(b)
1

167

 
691

284

AOCI
(57
)
(141
)
 
78

283

Less AOCI attributable to noncontrolling interests
1

(77
)
 
3

22

Currency translation adjustments AOCI ending balance
$
(4,743
)
$
(5,874
)
 
$
(4,743
)
$
(5,874
)
 
 
 
 
 
 
Beginning balance
$
(163
)
$
49

 
$
49

$
13

AOCI before reclasses – net of taxes of $(24), $(8), $(69) and $3
40

(50
)
 
(222
)
(16
)
Reclasses from AOCI – net of taxes of $(1), $4, $8 and $1(b)
13

25

 
64

28

AOCI
53

(25
)
 
(158
)
12

Less AOCI attributable to noncontrolling interests
—

(1
)
 
—

1

Cash flow hedges AOCI ending balance
$
(109
)
$
26

 
$
(109
)
$
26

 
 
 
 
 
 
Beginning balance
$
(5,991
)
$
(7,708
)
 
$
(7,024
)
$
(8,254
)
AOCI before reclasses – net of taxes of $(2), $13, $28 and $(35)
(74
)
7

 
145

(111
)
Reclasses from AOCI – net of taxes of $187, $164, $426 and $347(b)
678

632

 
1,495

1,294

AOCI
604

639

 
1,640

1,183

Less AOCI attributable to noncontrolling interests
—

(6
)
 
3

(8
)
Benefit plans AOCI ending balance
$
(5,387
)
$
(7,063
)
 
$
(5,387
)
$
(7,063
)
 
 
 
 
 
 
AOCI at June 30
$
(10,194
)
$
(12,852
)
 
$
(10,194
)
$
(12,852
)

(a) Included adjustments of $(2,229) million and $(1,054) million for the three months ended June 30, 2020 and 2019, respectively and $(962) million and $(2,011) million for the six months ended June 30, 2020 and 2019, respectively, related to insurance liabilities and annuity benefits in our run-off insurance operations to reflect the effects that would have been recognized had the related unrealized investment security gains been realized. See Note 12 for further information.
(b) The total reclassification from AOCI included $836 million, including currency translation of $688 million, net of taxes, for the six months ended June 30, 2020, related to the sale of our BioPharma business within our Healthcare segment.